看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
9 w& s* S4 d: Q% y9 m
, G* }" ~- |1 o" Z0 C$ A! c: m
Currently available feasibility data for possible combination strategies. * V- m8 K& i# s* p7 x8 V4 s7 }
————————————————————————————————1 P/ q. p3 k6 H& ^& U2 ?
Combination Feasibility according to preliminary data 7 u* o7 m3 k4 F5 l0 b7 w
——————————————————————————————————/ j0 {) Q+ t9 O8 V/ D/ j
Bevacizumab + sorafenib Yes, reduced dose : I; h) D, c- L# Y+ F
Bevacizumab + sunitinib† No + T8 F2 W$ S0 j" V4 @0 w5 t, w
Bevacizumab + temsirolimus Yes & y; w) W' Z. V. ?2 h
Bevacizumab + everolimus Yes , F$ E5 P2 H, A2 }# i, j: W
Sorafenib + sunitinib ? - ~/ A- X3 e' G& v6 n
Sorafenib + temsirolimus Yes, reduced dose , @5 n3 {$ |4 j5 M, e) |2 l* a
Sorafenib + everolimus Yes, reduced dose 7 u- t# A5 e) v2 @! p( U
Sunitinib + temsirolimus† No e( e8 _3 V: |
Sunitinib + everolimus ?
; e& B$ E4 J1 Y" P3 r, e, lTemsirolimus + everolimus ? 6 R4 v* C% d; j' Q! g, z" ~
————————————————————
6 w% L' b; t8 o& U9 R†Led to US FDA warning.; V% J) q2 N/ U1 t+ L8 K
?: As yet unattempted combination.7 ^9 Z- i1 r7 Y: H
|
显身卡
